Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $27.00 by Analysts at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price cut by HC Wainwright from $28.00 to $27.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on ENTA. StockNews.com cut Enanta Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, April 6th. JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a research note on Thursday, February 8th. Finally, JMP Securities lowered their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a market outperform rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $19.00.

Enanta Pharmaceuticals Trading Down 10.3 %

NASDAQ ENTA opened at $13.10 on Tuesday. The stock’s 50-day moving average price is $14.91 and its two-hundred day moving average price is $12.08. The company has a market cap of $277.20 million, a PE ratio of -2.00 and a beta of 0.54. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $36.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. Research analysts forecast that Enanta Pharmaceuticals will post -4.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 445.6% in the 3rd quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company’s stock valued at $6,125,000 after buying an additional 448,201 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Enanta Pharmaceuticals by 613.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock worth $7,055,000 after purchasing an additional 543,111 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $1,253,000. Walleye Capital LLC lifted its holdings in Enanta Pharmaceuticals by 342.8% in the 3rd quarter. Walleye Capital LLC now owns 119,364 shares of the biotechnology company’s stock worth $1,333,000 after purchasing an additional 92,410 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter worth approximately $1,481,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.